Creative Bio-Peptides (CBP) was started in late 2017 with the mission to improve patients lives by challenging prevalent conventions about the causes and treatment approaches of neurodegenerative diseases. We seek to make a positive impact in people’s daily lives by reversing disease causing processes to improve a disabling condition. We strive to bring to market innovative therapeutics for important conditions caused by innate immune system activation in neuropathies, dementias, brain injuries, and substance use disorders.
We have created dozens of orally-active peptides representing over $75M in legacy research and development related to the first generation peptide (non-oral) which has been shown to be safe and effective in multiple controlled trials for improving cognitive endpoints in more severely impaired individuals (1, 2, 3). Our new oral lead compound RAP-103 is near phase 1 ready and is shown to be safe in animal toxicity studies with rapid brain entry and stability.
Our current developmental focus is in chronic pain conditions and neuropathies, such as Persistent Post-Surgical Pain (PPSP) and diabetic peripheral neuropathy (DPN). Chronic pain results from persistent innate immune activation that then damages neurons. RAP-103 (R103) blocks chronic pain without need for opioids (4), and enhances opioid potency to relieve pain at lower opioid doses. Blocking chemokine receptor activation also blunts drug-seeking behaviors in animals and R103 is being evaluated for its use in opioid use disorders with funding from NIDA, NIH. [1R43DA050349]
We are also developing our RAP peptides as treatments for cognitive decline in dementias and have been funded by the NIA, NIH [1R43AG071064]. Prior clinical success in reversing cognitive deficits in Neuro-AIDS with the non-oral peptide CCR5 antagonist DAPTA de-risks what has been a challenging therapeutic area and provides a treatment roadmap for many neurodegenerative conditions.
The next steps are to progress the lead peptide into human safety and pilot efficacy testing. We invite you to review the scientific information and clinical results provided throughout this web site, and to contact us if you have an interest to partner with us.
